Skip to main content

JAK/TYK2

Immunosuppression Increasing (2.23.2024)

Feb 23, 2024

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on RheumNow.com; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients.




  1. 2021 NHIS Survey data suggests the prevalence of immunosuppression in the USA is

Read Article

Five Takeaways in PsA/SpA at RNL 2024

Feb 20, 2024

Continuing with the theme of clinical pearls, the PsA and SpA speakers also provided a wealth of information. Here are my five key takeaways and clinical pearls. 

Read Article

Vasculitis Pearls

Once again RheumNow Live 2024 really delivered with high impact learning packed into short sessions. As someone with an interest in vasculitis it was fantastic to see four of my favorite speakers in the Vasculitis Mavens and STEP talks. They gave us what we really want from these talks –

Read Article
Brazilian registry of 1316 RA pts on bDMARDs or JAKi-Added use of antimalarials reduced SAEs & total AEs, & incr survival. 19% were on HCQ, & had signif less SAEs (mIRR: 0.49); AEs (0.68); serious infections (0.53); hepatic AEs (0.21); & mortality (P=.003) https://t.co/bAZ8m3OBo2 https://t.co/SlneyfbJIh
Dr. John Cush @RheumNow( View Tweet )
Feb 17, 2024

Sex Disparities in PsA/SpA

Feb 13, 2024

Dr. Eder delivered an illuminating talk at RheumNow Live 2024 on sex differences in psoriatic arthritis; the disease may manifest differently in men and women, and therapeutic responses may differ between the sexes.

Read Article
JAKi Rx pts w/ H.Zoster who continue JAKi are not at higher risk for recurrent HZ. 3947 (RA>UC pts on JAKi, 611 had HZ (8.38/100PY). 460 continued JAKi, 78 D/C. Recurrent HZ reactivation. after median 1.1 yrs was 5.3/100 vs. 5.9/100 PY; P = 0.52) https://t.co/FH0ysEkGiA https://t.co/lOHyaXzAn3
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2024

Favorable Survival w/ MDA-5 Ab+. 154 pts w/ MDA5+DM; 40 died (26%) Rx induction (mostly resp. failure). 114 survived, w/ 5-yr survival of 97% & relapse-free survival 77%. Survival improved w/ JAKi use (P=.03). 8% achieved complete drug-free remission. https://t.co/QkqM9IztEG https://t.co/yBCH85CpUN

Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2024

Co-management of Psoriatic Disease

It is a common clinical scenario to see someone with both severe psoriatic arthritis and skin psoriasis. In an ideal world this would involve a combined clinic with our local friendly dermatologist. For many of us, however, this is not practical for many reasons. The excellent Saturday morning

Read Article

VITAL Info on Autoimmune Disease (2.9.2024)

Feb 09, 2024

Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".




  1. Many #RA pts remain on Steroids despite b/tsDMARD use! Study 228 #RA pts,

Read Article
Full read, great review of JAK/STAT signaling and JAK inhibitors published in Ann Rheum Dis.-- Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story (Authored by JAK mavens) https://t.co/xen1Htkv2o https://t.co/5hX9hhuK77
Dr. John Cush @RheumNow( View Tweet )
Feb 04, 2024

Pre-Treatment Testing with Biologics Falls Short

Feb 01, 2024

US commercial insurance claim analysis of laboratory screening and monitoring practices in chronic inflammatory skin disease (CISD) patients shows that < 60% received the recommended pretreatment testing when starting systemic immunomodulatory treatment.

Read Article
Some takeways from JAK inhibitors in dermatology talk by Bruce Strober. Great talk. #RNL2024 @RheumNow https://t.co/fuRsSnnsha
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
Jan 27, 2024
Dermatology colleagues are using JAKis with success for wide range of dermatological diseases. Note the beauty of this slide with further elaboration on domain inhibition, cool stuff 🤓 Bruce Strober #RNL2024 @RheumNow https://t.co/2yHHcOgTC8
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
Jan 27, 2024
JAK toxicity of interest. Eric Ruderman #RNL2024 @RheumNow https://t.co/qdlJFKTUR8
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
Jan 27, 2024
I am jealous of the derms who have topical JAKi! Dr. Strober flaunts all the different JAKi he has at his disposal to treat derm diseases #RNL2024 @rheumnow https://t.co/qdMWCSA5I1
TheDaoIndex @KDAO2011( View Tweet )
Jan 27, 2024
JAK and TYK2 signaling pathways. Eric Ruderman #RNL2024 @RheumNow https://t.co/WxoZGCEL0z
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
Jan 27, 2024
JAKinib negatives. Eric Ruderman #RNL2024 @RheumNow https://t.co/vVzSQMVa5a
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
Jan 27, 2024
"Any vacuolar interface dermatitis will respond to a JAKi" - Dr. B Strober noted JAKi will work for cutaneous lupus #RNL2024 @rheumnow

TheDaoIndex @KDAO2011( View Tweet )

Jan 27, 2024
Dr. Winthrop avoid JAKi and TNFi in pts with chronic lung infections like MAI. #RNL2024 @rheumnow https://t.co/TfMa7hktL9
TheDaoIndex @KDAO2011( View Tweet )
Jan 27, 2024
Do you check CPK on patients who are on JAK inhibitors? #RNL2024 @rheumnow

TheDaoIndex @KDAO2011( View Tweet )

Jan 27, 2024
For pts on JAKi needing vaccines; to avoid diminishing vaccine efficacy, Dr. Winthrop noted he treats a JAKi like he would MTX in that he holds the JAKi a week after vaccinating. #RNL2024 @rheumnow

TheDaoIndex @KDAO2011( View Tweet )

Jan 27, 2024
Clinical pearl! Dr. Winthrop holds JAKi for one week after vaccination. #RNL2024 @RheumNow https://t.co/BLiKu8xX7t
Dr. Rachel Tate @uptoTate( View Tweet )
Jan 27, 2024